S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Taro Pharmaceutical Industries Stock Forecast, Price & News

-1.73 (-4.44%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
16,699 shs
Average Volume
25,182 shs
Market Capitalization
$1.40 billion
P/E Ratio
Dividend Yield
Price Target

Taro Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
95.9% Upside
$73.00 Price Target
Short Interest
0.69% of Float Sold Short
Dividend Strength
News Sentiment
0.61mentions of Taro Pharmaceutical Industries in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.91 out of 5 stars

Medical Sector

590th out of 1,433 stocks

Pharmaceutical Preparations Industry

285th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Taro Pharmaceutical Industries logo

About Taro Pharmaceutical Industries (NYSE:TARO) Stock

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

TARO Stock News Headlines

Taro Pharmaceutical Q1 2022 Earnings Preview
Taro Pharmaceutical Indus Earnings Preview
Taro to Announce Full Year Results on May 26, 2022
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
$58.27 million
Pretax Margin


Sales & Book Value

Annual Sales
$561.35 million
Cash Flow
$4.11 per share
Book Value
$45.54 per share


Free Float
Market Cap
$1.40 billion

Taro Pharmaceutical Industries Frequently Asked Questions

Should I buy or sell Taro Pharmaceutical Industries stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Taro Pharmaceutical Industries stock.
View analyst ratings for Taro Pharmaceutical Industries
or view top-rated stocks.

What is Taro Pharmaceutical Industries' stock price forecast for 2022?

1 Wall Street analysts have issued 12 month price targets for Taro Pharmaceutical Industries' stock. Their TARO stock forecasts range from $73.00 to $73.00. On average, they predict Taro Pharmaceutical Industries' share price to reach $73.00 in the next year. This suggests a possible upside of 95.9% from the stock's current price.
View analysts' price targets for Taro Pharmaceutical Industries
or view top-rated stocks among Wall Street analysts.

How has Taro Pharmaceutical Industries' stock performed in 2022?

Taro Pharmaceutical Industries' stock was trading at $50.11 at the beginning of the year. Since then, TARO stock has decreased by 25.6% and is now trading at $37.26.
View the best growth stocks for 2022 here

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 65,500 shares, a decline of 30.2% from the May 31st total of 93,800 shares. Based on an average trading volume of 30,900 shares, the days-to-cover ratio is currently 2.1 days. Currently, 0.7% of the company's shares are short sold.
View Taro Pharmaceutical Industries' Short Interest

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Tuesday, July 26th 2022.
View our earnings forecast for Taro Pharmaceutical Industries

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) released its quarterly earnings results on Thursday, May, 26th. The company reported $0.73 EPS for the quarter, missing the consensus estimate of $0.88 by $0.15. The company earned $143.26 million during the quarter, compared to the consensus estimate of $147 million. Taro Pharmaceutical Industries had a trailing twelve-month return on equity of 7.10% and a net margin of 10.38%. During the same period in the previous year, the business earned $0.81 earnings per share.
View Taro Pharmaceutical Industries' earnings history

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the following people:
  • Mr. Uday V. Baldota, CEO & Director (Age 52)
  • Mr. William J. Coote, VP, CFO & Chief Accounting Officer (Age 67)
  • Mr. Itamar Karsenti, VP & Head of Operations (Age 50)
  • Mr. Avi Avramoff, VP and Head of R&D (Age 57)
  • Mr. Itzik Baruch, VP of Technical Services (Age 59)
  • Dr. Roman Kaplan, VP of Scientific and Technical Compliance Mang. (Age 75)
  • Mr. Erik Zwicker J.D., VP, Gen. Counsel & Sec. (Age 42)
  • Mr. Ara Aprahamian, VP of Sales & Marketing (Age 54, Pay $616.14k)
  • Ms. Michele Visosky, VP & Head of Human Resource (Age 56)
  • Mr. Jayesh Shah, Head of Procurement (Age 66)

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries CEO Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among Taro Pharmaceutical Industries' employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $37.26.

How much money does Taro Pharmaceutical Industries make?

Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $1.40 billion and generates $561.35 million in revenue each year. The company earns $58.27 million in net income (profit) each year or $1.55 on an earnings per share basis.

How many employees does Taro Pharmaceutical Industries have?

Taro Pharmaceutical Industries employs 1,417 workers across the globe.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for Taro Pharmaceutical Industries is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169.

This page (NYSE:TARO) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.